Abstract
Anhedonia, defined as lowered ability to experience physical or social pleasure, is a frequent symptom in patients with Parkinson’s disease (PD). In this population, most studies report an association of anhedonia with neuropsychiatric disorders and syndromes such as depression, apathy and cognitive decline. Reports on the relationship between anhedonia and severity of motor symptoms in PD are inconclusive. The presence of anhedonia is diagnosed on the basis of history and mental status examination; its severity can be assessed by available rating scales. Several studies described anhedonia as strictly associated to depression in PD and probably related to degeneration of mesolimbic and mesocortical dopamine projections, thus contributing directly to the high incidence of depression and consequently of anhedonia in PD patients. This is supported by the observation that inhibition of dopamine system via D2 receptor antagonists can be accompanied by reduced motivation, drive and spontaneity, and dysphoria.
In contrast to PD, data on anhedonia in other movement disorders are still scarce.
Future research should be directed to a better understanding of the etiology and pathophysiology of anhedonia in order to be able to identify and provide new strategies for treatment of this neuropsychiatric phenomenon.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- DBS-STN:
-
Deep brain stimulation of the subthalamic nucleus
- DSM:
-
Diagnostic and Statistical Manual of Mental Disorders
- DSM-IV-TR:
-
The fourth revised edition of the DSM
- ICD-10:
-
International Classification of Diseases
- PD:
-
Parkinson’s disease
References
de Rijk MC, Rocca WA, Anderson DW, et al. A population perspective on diagnostic criteria for Parkinson’s disease. Neurology. 1997;48(5):1277–81.
Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641–9.
Leentjens AFG. Epidemiology of psychiatric symptoms in Parkinson’s disease. Adv Biol Psychiatry. 2012;27:1–12.
Wolters EC. Dopaminomimetic psychosis in Parkinson’s disease patients: diagnosis and treatment. Neurology. 1999;52(7 Suppl 3):S10–3.
Leentjens AF, Van den Akker M, Metsemakers JF, et al. Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord. 2003;18(4):414–8.
Schuurman AG, van den Akker M, Ensinck KT, et al. Increased risk of Parkinson’s disease after depression: a retrospective cohort study. Neurology. 2002;58(10):1501–4.
Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case–control study. Mov Disord. 2000;15(4):669–77.
Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.
Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3(3):243–54.
Kitanaka J, Kitanaka N, Takemura M. Neurochemical consequences of dysphoric state during amphetamine withdrawal in animal models: a review. Neurochem Res. 2008;33(1):204–19.
Stevens A, Peschk I, Schwarz J. Implicit learning, executive function and hedonic activity in chronic polydrug abusers, currently abstinent polydrug abusers and controls. Addiction. 2007;102(6):937–46.
Vacca G, Ahn S, Phillips AG. Effects of short-term abstinence from escalating doses of D-amphetamine on drug and sucrose-evoked dopamine efflux in the rat nucleus accumbens. Neuropsychopharmacology. 2007;32(4):932–9.
Cohen AS, Leung WW, Saperstein AM, et al. Neuropsychological functioning and social anhedonia: results from a community high-risk study. Schizophr Res. 2006;85(1–3):132–41.
Gard DE, Kring AM, Gard MG, et al. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res. 2007;93(1–3):253–60.
Winograd-Gurvich C, Fitzgerald PB, Georgiou-Karistianis N, et al. Negative symptoms: a review of schizophrenia, melancholic depression and Parkinson’s disease. Brain Res Bull. 2006;70(4–6):312–21.
Harvey PO, Pruessner J, Czechowska Y, et al. Individual differences in trait anhedonia: a structural and functional magnetic resonance imaging study in non-clinical subjects. Mol Psychiatry. 2007;12(8):703, 767–75.
Di Giuda D, Camardese G, Bentivoglio AR, et al. Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging. 2012;39(12):1937–48.
Kim WH, Lee YS, Jung SH, et al. Major depressive disorder preceding the onset of progressive supranuclear palsy. Psychiatry Invest. 2009;6(2):112–4.
Miller KM, Okun MS, Fernandez HF, et al. Depression symptoms in movement disorders: comparing Parkinson’s disease, dystonia, and essential tremor. Mov Disord. 2007;22(5):666–72.
Paulsen JS, Nehl C, Hoth KF, et al. Depression and stages of Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2005;17(4):496–502.
Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2010;25(8):1077–81.
Vaccarino AL, Sills T, Anderson KE, et al. Assessment of depression, anxiety and apathy in prodromal and early Huntington disease. PLoS Curr. 2011;3:RRN1242.
Ribot TH. The psychology of emotions. London: W Scott Pub. Co.; New York: C. Scribner’s; 1903.
APA. Diagnostic and statistical manual of mental disorders. 3rd ed. (DSM-III) Washington, DC: APA; 1980.
WHO. The ICD–10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: WHO; 1992.
APA. Diagnostic and statistical manual of mental disorders 4th text revised (DSM-IV-TR). Washington, DC: APA; 2000.
Sims A. Symptoms in the mind. London: Balliere Tindall; 1988.
Loas G, Krystkowiak P, Godefroy O. Anhedonia in Parkinson’s disease: an overview. J Neuropsychiatry Clin Neurosci. 2012;24(4):444–51.
Leentjens AFG, Dujardin K, Marsh L, et al. Apathy and anhedonia rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23(14):2004–14.
Assogna F, Cravello L, Caltagirone C, et al. Anhedonia in Parkinson’s disease: a systematic review of the literature. Mov Disord. 2011;26(10):1825–34.
Weintraub D, Cary MS, Stern MB, et al. Daily affect in Parkinson disease is responsive to life events and motor symptoms. Am J Geriatr Psychiatry. 2006;14(2):161–8.
Robert P, Onyike CU, Leentjens AF, et al. Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. Eur Psychiatry. 2009;24(2):98–104.
APA. Diagnostic and statistical manual of mental disorder. 4th ed. (DSM-IV) Washington, DC: APA; 1994.
Snaith RP, Hamilton M, Morley S, et al. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995;167(1):99–103.
Chapman LJ, Chapman JP, Raulin ML. Scales for physical and social anhedonia. J Abnorm Psychol. 1976;85(4):374–82.
Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2007;22(8):1077–92.
Isella V, Iurlaro S, Piolti R, et al. Physical anhedonia in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2003;74(9):1308–11.
Lemke MR, Brecht HM, Koester J, et al. Anhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci. 2005;17(2):214–20.
Reichmann H, Brecht MH, Koster J, et al. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson’s disease. CNS Drugs. 2003;17(13):965–73.
Dujardin K, Sockeel P, Devos D, et al. Characteristics of apathy in Parkinson’s disease. Mov Disord. 2007;22(6):778–84.
Pluck GC, Brown RG. Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73(6):636–42.
Starkstein SE, Merello M, Jorge R, et al. The syndromal validity and nosological position of apathy in Parkinson’s disease. Mov Disord. 2009;24(8):1211–6.
Drijgers RL, Dujardin K, Reijnders JS, et al. Validation of diagnostic criteria for apathy in Parkinson’s disease. Parkinsonism Relat Disord. 2010;16(10):656–60.
Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008;23(2):183–9; quiz 313.
Fibiger HC. The neurobiological substrates of depression in Parkinson’s disease: a hypothesis. Can J Neurol Sci. 1984;11(1 Suppl):105–7.
Cantello R, Aguggia M, Gilli M, et al. Major depression in Parkinson’s disease and the mood response to intravenous methylphenidate: possible role of the “hedonic” dopamine synapse. J Neurol Neurosurg Psychiatry. 1989;52(6):724–31.
Fleminger S. Left-sided Parkinson’s disease is associated with greater anxiety and depression. Psychol Med. 1991;21(3):629–38.
Rockwell E, Choure J, Galasko D, et al. Psychopathology at initial diagnosis in dementia with Lewy bodies versus Alzheimer disease: comparison of matched groups with autopsy-confirmed diagnoses. Int J Geriatr Psychiatry. 2000;15(9):819–23.
Lemke MR, Brecht HM, Koester J, et al. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson’s disease. J Neurol Sci. 2006;248(1–2):266–70.
Lieberman A. Are dementia and depression in Parkinson’s disease related? J Neurol Sci. 2006;248:138–42.
Ehrt U, Bronnick K, Leentjens AF, et al. Depressive symptom profile in Parkinson’s disease: a comparison with depression in elderly patients without Parkinson’s disease. Int J Geriatr Psychiatry. 2006;21(3):252–8.
Zheng J, Sun S, Qiao X, et al. Depression in patients with Parkinson’s disease and the associated features. J Huazhong Univ Sci Technolog Med Sci. 2009;29(6):725–8.
Santangelo G, Vitale C, Trojano L, et al. Relationship between depression and cognitive dysfunctions in Parkinson’s disease without dementia. J Neurol. 2009;256(4):632–8.
Santangelo G, Morgante L, Savica R, et al. Anhedonia and cognitive impairment in Parkinson’s disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. Parkinsonism Relat Disord. 2009;15(8):576–81.
Pouladi MA, Graham RK, Karasinska JM, et al. Prevention of depressive behaviour in the YAC 128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain. 2009;132:919–32.
Kaji Y, Hirata K. Apathy and anhedonia in Parkinson’s disease. ISRN Neurol. 2011;2011:219427.
Fujiwara S, Kimura F, Hosokawa T, et al. Anhedonia in Japanese patients with Parkinson’s disease. Geriatr Gerontol Int. 2011;11(3):275–81.
Miura S, Kida H, Nakajima J, et al. Anhedonia in Japanese patients with Parkinson’s disease: analysis using the Snaith-Hamilton Pleasure Scale. Clin Neurol Neurosurg. 2012;114(4):352–5.
Zahodne LB, Marsiske M, Okun MS, et al. Components of depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2012;25(3):131–7.
Zahodne LB, Marsiske M, Bowers D. A latent class analysis of psychological disturbance in Parkinson’s disease. Int J Geriatr Psychiatry. 2013;28:1054–60. doi:10.1002/gps.3927.
Spalletta G, Fagioli S, Meco G, et al. Hedonic tone and its mood and cognitive correlates in Parkinson’s disease. Depress Anxiety. 2013;30(1):85–91.
Snaith RP. Identifying depression: the significance of anhedonia. Hosp Pract (Off Ed). 1993;28(9A):55–60.
Taylor AE, Saint-Cyr JA. Depression in Parkinson’s disease: reconciling physiological and psychological perspectives. J Neuropsychiatry Clin Neurosci. 1990;2(1):92–8.
Poewe W. Non-motor symptoms in Parkinson’s disease. Eur J Neurol. 2008;15 Suppl 1:14–20.
Witt K, Daniels C, Herzog J, et al. Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2006;18(3):397–401.
Bermanzohn PC, Siris SG. Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia. Compr Psychiatry. 1992;33(4):221–32.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427–42.
Aarsland D, Bronnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2009;80(8):928–30.
Oguru M, Tachibana H, Toda K, et al. Apathy and depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2010;23(1):35–41.
Troster AI, Stalp LD, Paolo AM, et al. Neuropsychological impairment in Parkinson’s disease with and without depression. Arch Neurol. 1995;52(12):1164–9.
Pedersen KF, Alves G, Aarsland D, et al. Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study. J Neurol Neurosurg Psychiatry. 2009;80(11):1279–82.
Holroyd S, Currie LJ, Wooten GF. Depression is associated with impairment of ADL, not motor function in Parkinson disease. Neurology. 2005;64(12):2134–5.
Liu CY, Wang SJ, Fuh JL, et al. The correlation of depression with functional activity in Parkinson’s disease. J Neurol. 1997;244(8):493–8.
Global Parkinson’s Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord. 2002;17(1):60–7.
Hobson P, Holden A, Meara J. Measuring the impact of Parkinson’s disease with the Parkinson’s Disease Quality of Life questionnaire. Age Ageing. 1999;28(4):341–6.
Ravina B, Camicioli R, Como PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007;69(4):342–7.
Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308–12.
Royall DR, Mahurin RK, Gray KF. Bedside assessment of executive cognitive impairment: the executive interview. J Am Geriatr Soc. 1992;40(12):1221–6.
Heinz A, Schmidt LG, Reischies FM. Anhedonia in schizophrenic, depressed, or alcohol-dependent patients–neurobiological correlates. Pharmacopsychiatry. 1994;27 Suppl 1:7–10.
Uhl GR, Hedreen JC, Price DL. Parkinson’s disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology. 1985;35(8):1215–8.
Javoy-Agid F, Agid Y. Is the mesocortical dopaminergic system involved in Parkinson disease? Neurology. 1980;30(12):1326–30.
Kunig G, Leenders KL, Martin-Solch C, et al. Reduced reward processing in the brains of Parkinsonian patients. Neuroreport. 2000;11(17):3681–7.
Braak H, Braak E. Pathoanatomy of Parkinson’s disease. J Neurol. 2000;247 Suppl 2:II3–10.
Bench CJ, Friston KJ, Brown RG, et al. Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions. Psychol Med. 1993;23(3):579–90.
Bressan RA, Crippa JA. The role of dopamine in reward and pleasure behaviour–review of data from preclinical research. Acta Psychiatr Scand. 2005;111 Suppl 427:14–21. doi:10.1111/j.1600-0447.2005.00540.x.
Grafton ST. Contributions of functional imaging to understanding parkinsonian symptoms. Curr Opin Neurobiol. 2004;14(6):715–9.
Heinz A, Dufeu P, Kuhn S, et al. Psychopathological and behavioral correlates of dopaminergic sensitivity in alcohol-dependent patients. Arch Gen Psychiatry. 1996;53(12):1123–8.
Knable MB, Jones DW, Coppola R, et al. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson’s disease. J Nucl Med. 1995;36(7):1216–25.
Malhi GS, Parker GB, Greenwood J. Structural and functional models of depression: from sub-types to substrates. Acta Psychiatr Scand. 2005;111(2):94–105.
Pizzagalli DA, Oakes TR, Fox AS, et al. Functional but not structural subgenual prefrontal cortex abnormalities in melancholia. Mol Psychiatry. 2004;9(4):325, 393–405.
Carey RJ. An examination of parkinsonian versus anhedonia contributions to self-stimulation impairments induced by dopamine dysfunction. Behav Brain Res. 1986;22(2):117–25.
Wise RA, Spindler J, deWit H, et al. Neuroleptic-induced “anhedonia” in rats: pimozide blocks reward quality of food. Science. 1978;201(4352):262–4.
Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl). 2004;171(2):121–32.
Scharfetter C. General psychopathology: an introduction. Cambridge: Cambridge University Press; 1980.
Delaville C, Chetrit J, Abdallah K, et al. Emerging dysfunctions consequent to combined monoaminergic depletions in Parkinsonism. Neurobiol Dis. 2012;45(2):763–73.
Rampersaud N, Harkavyi A, Giordano G, et al. Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson’s disease with noradrenergic deficit. Br J Pharmacol. 2012;167(7):1467–79.
Berridge KC, Kringelbach ML. Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacology (Berl). 2008;199(3):457–80.
Faure A, Richard JM, Berridge KC. Desire and dread from the nucleus accumbens: cortical glutamate and subcortical GABA differentially generate motivation and hedonic impact in the rat. PLoS One. 2010;5(6):e11223.
Rolls ET, Kringelbach ML, de Araujo IE. Different representations of pleasant and unpleasant odours in the human brain. Eur J Neurosci. 2003;18(3):695–703.
Keedwell PA, Andrew C, Williams SC, et al. The neural correlates of anhedonia in major depressive disorder. Biol Psychiatry. 2005;58(11):843–53.
Salamone JD, Correa M, Mingote S, et al. Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. J Pharmacol Exp Ther. 2003;305(1):1–8.
Volkow ND, Wang GJ, Fischman MW, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature. 1997;386(6627):827–30.
Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol. 1998;80(1):1–27.
Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev. 1998;28(3):309–69.
Hazy TE, Frank MJ, O’Reilly RC. Neural mechanisms of acquired phasic dopamine responses in learning. Neurosci Biobehav Rev. 2010;34(5):701–20.
Reichmann H, Odin P, Brecht HM, et al. Changing dopamine agonist treatment in Parkinson’s disease: experiences with switching to pramipexole. J Neural Transm Suppl. 2006;71:17–25.
Lemke MR. Depressive symptoms in Parkinson’s disease. Eur J Neurol. 2008;15 Suppl 1:21–5.
Drijgers RL, Verhey FR, Tissingh G, et al. The role of the dopaminergic system in mood, motivation and cognition in Parkinson’s disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate. J Neurol Sci. 2012;320(1–2):121–6.
Chaudhuri RK, Martinez-Martin P, Antonini A, et al. Rotigotine and specific non-motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013;19(7):660–5.
Maj M, Veltro F, Pirozzi R, et al. Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry. 1992;149(6):795–800.
Willner P, Lappas S, Cheeta S, et al. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology (Berl). 1994;115(4):454–62.
Kondo T. Dopamine dysregulation syndrome. Hypothetical application of reward system stimulation for the treatment of anhedonia in Parkinson’s disease patients. J Neurol. 2008;255 Suppl 4:14–8.
Giovannoni G, O’Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68(4):423–8.
Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90–9.
Picillo M, Rocco M, Barone P. Dopamine receptor agonists and depression in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15 Suppl 4:S81–4.
Pizzagalli DA, Holmes AJ, Dillon DG, et al. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry. 2009;166(6):702–10.
Demyttenaere K, De Fruyt J, Stahl SM. The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol. 2005;8(1):93–105.
Schrijvers D, Hulstijn W, Sabbe BG. Psychomotor symptoms in depression: a diagnostic, pathophysiological and therapeutic tool. J Affect Disord. 2008;109(1–2):1–20.
Stein DJ. Depression, anhedonia, and psychomotor symptoms: the role of dopaminergic neurocircuitry. CNS Spectr. 2008;13(7):561–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Spalletta, G., Assogna, F., Caltagirone, C., Leentjens, A.F.G. (2014). Anhedonia in Parkinson’s Disease and Other Movement Disorders. In: Ritsner, M. (eds) Anhedonia: A Comprehensive Handbook Volume II. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-8610-2_13
Download citation
DOI: https://doi.org/10.1007/978-94-017-8610-2_13
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-8609-6
Online ISBN: 978-94-017-8610-2
eBook Packages: MedicineMedicine (R0)